Steris (Steris) GF Value : $252.51 (As of May. 07, 2024)

View and export this data going back to 1992. Start your Free Trial

What is Steris GF Value?

The GF Value represents the current intrinsic value of a stock derived from our exclusive method. The GF Value Line on our summary page gives an overview of the fair value that the stock should be traded at. It is calculated based on three factors:

Historical multiples (PE Ratio, PS Ratio, PB Ratio and Price-to-Free-Cash-Flow) that the stock has traded at.
GuruFocus adjustment factor based on the company’s past returns and growth.
Future estimates of the business performance.

We believe the GF Value Line is the fair value that the stock should be traded at. The stock price will most likely fluctuate around the GF Value Line. If the stock price is significantly above the GF Value Line, it is overvalued and its future return is likely to be poor. On the other hand, if it is significantly below the GF Value Line, its future return will likely be higher.

Please note, "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

As of today (2024-05-07), Steris's share price is $213.30. Steris's GF Value is $252.51. Therefore, Steris's Price-to-GF-Value for today is 0.84.

Based on the relationship between the current stock price and the GF Value, GuruFocus believes Steris is Modestly Undervalued.

Steris (NYSE:STE) GF Value Explanation

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

Posssible Evaluations	All-in-One Screener Examples (2)
Possible Value Trap, Think Twice (1)	Predictable Companies that possibly be Value Traps
Significantly Overvalued	Predictable Companies which are Significantly Overvalued
Modestly Overvalued	Predictable Companies which are Modestly Overvalued
Fairly Valued	Predictable High Quality Companies which are Fairly Valued
Modestly Undervalued (3)	Predictable High Quality Companies which are Modestly Undervalued
Significantly Undervalued (3)	Predictable High Quality Companies which are Significantly Undervalued

(1) "Possible Value Trap, Think Twice" is for the companies that look very undervalued, but either in the long term trend of business decline, or in financial distress.

(2) These are some simple examples. You can access our GF Valuation filter under All-in-One Screener’s Fundamental tab, and Price-to-GF-Value filter under Valuation Ratio tab and set your own criteria.

(3) There is only a sufficient margin of safety when the stock is undervalued.

Steris's Price-to-GF-Value for today is calculated as

Price-to-GF-Value	=	Share Price	/	GF Value
	=	213.30	/	252.51
	=	0.84

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Steris GF Value Related Terms

Thank you for viewing the detailed overview of Steris's GF Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Steris (Steris) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Steris PLC (NYSE:STE) » Definitions » GF Value

Comparable Companies

Traded in Other Exchanges

S1TE34:Brazil

Address

5960 Heisley Road, Mentor, OH, USA, 44060

Website

https://www.steris-ir.com

Steris is an Ireland-domiciled medical device company focused on sterilization services and infection prevention. The company is the global leader in contract sterilization services, ensuring the safe delivery of single-use and implantable medical equipment to hospitals around the world. Additionally, Steris sells sterilizers, washer-disinfectors, and other decontamination equipment and supplies for use by care provider facilities and in biopharma manufacturing sites. Domiciled in the United States before its 2015 inversion to Ireland, the firm continues to derive roughly 70% of revenue from its U.S. operations, 10% from the United Kingdom, and the remaining 20% from other international regions.

Executives

Richard C Breeden	director	100 SOUTH WACKER, SUITE 1800, CHICAGO IL 60606
Cynthia L Feldmann	director	17 WINTHROP ROAD, WAYLAND MA 01778
Jacqueline B Kosecoff	director	5960 HEISLEY ROAD, MENTOR OH 44060
Mohsen Sohi	director	C/O STERIS CORPORATION, 5960 HEISLEY ROAD, MENTOR OH 44060
Esther M. Alegria	director	2642 MICHELLE DRIVE, SUITE 200, TUSTIN CA 92780
Cary L Majors	officer: VP, N America Com Operations	5960 HEISLEY ROAD, MENTOR OH 44060
John Adam Zangerle	director, officer: Sr. VP, Gen Counsel, and Sec.	5960 HEISLEY ROAD, MENTOR OH 44060
Michael J Tokich	director, officer: Sr. Vice Pres., CFO	C/O STERIS CORP, 5960 HEISLEY RD, MENTOR OH 44060
Karen L Burton	officer: VP, Controller & CAO	5960 HEISLEY ROAD, MENTOR OH 44060
Renato Tamaro	officer: V.P. & Corporate Treasurer	5960 HEISLEY ROAD, MENTOR OH 44060
Andrew Xilas	officer: SVP and GM, Dental	5960 HEISLEY ROAD, MENTOR OH 44060
Paul Edward Martin	director	C/O UNISYS CORPORATION, 801 LAKEVIEW DRIVE, SUITE 100, BLUE BELL PA 19422
Julia Madsen	officer: Senior VP, Life Sciences	5960 HEISLEY ROAD, MENTOR OH 44060
David B Lewis	director
Rosebrough Walter M Jr	officer: President & CEO	5960 HEISLEY ROAD, MENTOR OH 44060